North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
Moreno-Aspitia
Alvaro
A
Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.
Perez
Edith A
EA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D051242:Caveolin 1 / Q000097:blood; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D015337:Multicenter Studies as Topic / Q000379:methods; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage; D000093542:Gemcitabine
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D051242:Caveolin 1; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine